RxDoctor Payments Data

Katherine Bonnichsen, MD

Dermatology · Pierre, SDNPI 1003234832

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.7% of the total across 102 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by AbbVie at 25.4% of the total.

$1,894in general payments, 2019–2025

Across 102 payments — averaging $18.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$482
  • Lilly USA, LLC$379
  • Novartis$285
  • Regeneron Healthcare Solutions, Inc.$163
  • Pfizer$111
  • Amgen$105
  • plus $370 from 10 others

What the payments were for

  • Food & beverage$1,81296%
  • Education$824%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,894 in reported general payments places this provider in the 60th percentile of 44 dermatology providers in South Dakota.

See all dermatology providers in South Dakota

Medicare billing

Part B allowed, 2024
$121,689
Medicare patients
711
Services billed
3,166

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast63$296,307
Skyrizi PenRisankizumab-Rzaa11$208,625
Dupixent PenDupilumab11$39,973
Acitretin13$5,310
Fluorouracil57$4,728
Fluocinonide34$2,146
Mycophenolate Mofetil20$1,351
Ketoconazole72$1,269
Tacrolimus12$1,204
Metronidazole17$977
Clobetasol Propionate15$851
Triamcinolone Acetonide69$718
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc21$633
Betamethasone Dipropionate14$444
Doxycycline Hyclate27$373

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$105$296,30763 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 44 dermatology providers in South Dakota.

Other dermatology in Pierre

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →